Welcome to BioSeeker Group!

Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5570
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides.

    To find out more about Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part II: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
4SC
7TM Pharma
AB Science
Abbott
Abiogen
Acceleron Pharma
Access
ACT Biotech
Advanced Life Sciences
Advenchen
AEgera
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alethia Biotherapeutics
Allist Pharmaceuticals
Allostera
Allosterix
Alnylam
AlphaVax
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Ansaris
Antisoma
Aphios
AplaGen Biopharmaceuticals
Apogee Biotechnology
Apogenix
ApopLogic Pharmaceuticals
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Baxter International
Bayer
Benitec
Berkeley Lab
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
Biomas
Bionovo
Biotecnol
Biotica Technology
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
Catalyst Biosciences
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Cephalon
CerRx
ChemoCentryx
Chemokine Therapeutics
Chiasma
Chlorogen
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
Clinuvel
CombinatoRx
CompleGen
Compugen
CoNCERT Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokine PharmaSciences
Cytopia
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Digna Biotech
Dongkook Pharm
Dyax
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Erimos
Esperance Pharmaceuticals
Exelixis
Formula Pharmaceuticals
Galapagos
Galena Biopharma
Generex
GENova Biotherapeutics
Genovax
Genta
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Glycotope
GP Pharm
GPC Biotech
Green Cross
Gryphon Therapeutics
Hanmi
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hypha Discovery
Idera Pharmaceuticals
ImClone Systems
ImmunoCellular Therapeutics
ImmunoFrontier
Immunotope
ImmuPharma
Incozen Therapeutics
Incyte Corporation
Infinity Pharmaceuticals
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intellikine
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirax
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Lexicon Pharmaceuticals
Ligand
Lorus Therapeutics
Marillion Pharmaceuticals
Marina Biotech
MaxoCore Pharmaceuticals
MBiotec
Meda
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Myrexis
Nano Terra
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
NPS Pharmaceuticals
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
OXiGENE
PanaGin
Pathway Therapeutics
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Proacta
Progenics Pharmaceuticals
ProMetic Life Sciences
Protagonist
Provid
Q Chip
QLT
Quantum Pharmaceuticals
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regulon
Rexahn
Rigel
Rosetta Genomics
Samtheo Biopharma
Sanofi
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Senesco Technologies
Sentinel Oncology
Serometrix
SGX Pharmaceuticals
Shire
Sigma-Tau
Silence Therapeutics
Soligenix
Spectrum Pharmaceuticals
SRI International
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Tactic Pharma
Takeda
Tamir Biotechnology
Targa Therapeutics
TargeGen
TauTaTis
Taxolog
TCD Pharma
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
TransTech Pharma
UCB
UMN Pharma
Unigene
United Biomedical
ValiRx
VasGene Therapeutics
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
Viragen
Viralytics
ViroMed
ViroTarg
VM Discovery
Wyeth
Xcovery
Xencor
Xigen
YM BioSciences
Zelos Therapeutics
Zensun
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
ABT-510
AC-480
AE-37
AEG-35156
AEZS-108
AF-802
afamelanotide
afatinib
alvocidib
AME-133
AMG-386
angiopep+paclitaxel
Angiozyme
apatinib
APG-101
AR-42
ARQ-197
AS-101
AS-1411
AT-7519
AT-9283
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belinostat
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bortezomib
bosutinib
brivanib alaninate
BZL-101
Cabozantinib
CAL-101
canfosfamide hydrochloride
CBP-501
CC-223
cediranib
cenersen
cintredekin besudotox
conatumumab
corticorelin acetate
crizotinib
crolibulin
dacomitinib
danusertib
dasatinib
deslorelin
dinaciclib
dovitinib lactate
dulanermin
E-75
emepepimut-S
endoxifen
ENMD-2076
enzastaurin hydrochloride
EP-100
erlotinib
everolimus
foretinib
fosbretabulin tromethamine
fostamatinib disodium
FPI-01
gataparsen
gefitinib
goserelin
GSK-2118436
GT-111
GV-1001
GX-301
HE-3235
Her-2/Neu peptides
histrelin
ibritumomab tiuxetan
IC-83
icrucumab
idronoxil
imatinib mesilate
imetelstat
imMucin
INCB-028060
INSM-18
IPP-204106
ISA-P53-01
JI-101
kahalalide F
KD032
KX2-391
lanreotide
lapatinib ditosylate
lenvatinib
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
linifanib
linsitinib
litronesib
lonaprisan
lumiliximab
LY-2090314
mapatumumab
masitinib
MDX-1379
MGCD-265
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
mocetinostat
motesanib diphosphate
motexafin gadolinium
MVA-BN Her-2 vaccine
NAFB001
navitoclax
neratinib
netupitant
nilotinib
noscapine
NPB-001-056
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ON-01910
onartuzumab
Oncohist
OSI-027
OTS-102
ozarelix
P276-00
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
PD-0332991
pegdinetanib
perifosine
PHA-848125AC
plitidepsin
polyclonal antibody stimulator
ponatinib
PX-12
PX-866
quarfloxacin
quinacrine
quizartinib dihydrochloride
R-(-)-gossypol
RAF-265
ramucirumab
regorafenib
retaspimycin
ridaforolimus
rilotumumab
rindopepimut
romurtide
ruxolitinib
RX-0201-N
sagopilone
SCH-900776
seliciclib
sirolimus
sorafenib tosylate
sotatercept
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
Survivac
talmapimod
tandutinib
telatinib
temsirolimus
terameprocol
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
tivozanib
TL-32711
TM-30339
triciribine phosphate
TRU-016
vandetanib
vapreotide, immediate-release
varlitinib
vemurafenib
vitespen
volasertib
vosaroxin
VX-001
XL-147
XL-281
XL-413
XL-647
XL-765

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides.
    To find out more about Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Lymphoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lymphoma and Prostate Cancer. Learn More


Triple Analysis: Lymphoma, Melanoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Lymphoma, Melanoma and Pancreatic Cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Pancreatic Cancer and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Pancreatic Cancer and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Leukemia, Melanoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Learn More